Skip to main content
menu

Richard Dunne, M.D., M.S.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 273-1051

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

When a patient is diagnosed with cancer, he or she is faced with a lot of questions and uncertainty of what the future holds. My philosophy is to provide as much information as possible so that patients can make the best decisions for themselves and their families and so that together we can face any fears or worries head on.

I chose this field because my hope is to make the lives of cancer patients better – whether it is through direct patient care or my research, which focuses on pancreatobiliary cancers, as well as weight loss and muscle wasting related to cancer.

In addition to being passionate about cancer care, I have many interests outside of work that I enjoy sharing with my patients such as sports, travel and music.

Conditions I Treat

- Esophageal cancer
- Gastric cancer
- Liver cancer
- Pancreatic cancer
- Colorectal cancer
- Anal cancer

Credentials

Specialties

    Education

    2009
    MD | SUNY Downstate Health Sciences University - College of Medicine

    2021
    MS | University of Rochester

    Post-doctoral Training & Residency

    07/01/2016 - 06/30/2019
    Fellowship in Research at University of Rochester Medical Center

    07/01/2013 - 06/30/2015
    Fellowship in Hematology & Oncology at University of Rochester Medical Center

    06/25/2010 - 06/24/2012
    Residency in Internal Medicine at University of Rochester Medical Center

    06/25/2009 - 06/24/2010
    Internship in Internal Medicine at University of Rochester Medical Center

    VIEW ALL expand_more

    Awards

    2022 - 2027
    Cancer Grand Challenges: Understand and Reverse Cachexia
    Sponsor: National Cancer Institute and Cancer Research UK

    2020 - 2021
    Solid Tumor Faculty Leader in clinical trial accrual
    Location: Wilmot Cancer Institute

    2019 - 2021
    CTSI KL2 Career Development Award
    Location: University of Rochester Medical Center

    2017 - 2018
    Department of Medicine Research Pilot Grant Award

    2016 - 2019
    NIH R25 Fellowship Training Program in Cancer Control
    Location: University of Rochester Medical Center

    2015 - 2018
    Wilmot Foundation for Cancer Research Fellowship Award

    VIEW ALL expand_more

    Clinical Trials

    An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

    Lead Researcher: Richard F Dunne

    The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.

    View Study Details

    A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma,A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

    Lead Researcher: Richard F Dunne

    The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

    View Study Details

    Publications

    Journal Articles

    4/27/2023
    Ferrer M, Anthony TG, Ayres JS, Biffi G, Brown JC, Caan BJ, Cespedes Feliciano EM, Coll AP, Dunne RF, Goncalves MD, Grethlein J, Heymsfield SB, Hui S, Jamal-Hanjani M, Lam JM, Lewis DY, McCandlish D, Mustian KM, O'Rahilly S, Perrimon N, White EP, Janowitz T. "Cachexia: A systemic consequence of progressive, unresolved disease." Cell.. 2023 Apr 27; 186(9):1824-1845.

    2/2023
    Lin PJ, Altman BJ, Gilmore NJ, Loh KP, Dunne RF, Bautista J, Fung C, Janelsins MC, Peppone LJ, Melnik MK, Gococo KO, Messino MJ, Mustian KM. "Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors." Journal of the National Comprehensive Cancer Network : JNCCN.. 2023 Feb; 21(2):153-162.e2.

    12/22/2022
    Melucci AD, Lynch OF, Loria A, Mustian KM, Dunne RF, Temple LK, Fleming FJ. "A Novel Use for Pelvic Magnetic Resonance Imaging Scans to Estimate Lean Body Mass and Screen for Sarcopenia in Patients with Rectal Cancer." Diseases of the colon and rectum.. 2022 Dec 22; Epub 2022 Dec 22.

    VIEW ALL PUBLICATIONS

    Reviews

    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.